Sunshine Biopharma Announces Development Of An Orally Active Protease Inhibitor With Dose-Dependent Antiviral Activity In Mice With SARS-CoV-2)

Benzinga12/09 20:36

Aegis Capital Reiterates Buy on Sunshine Biopharma, Maintains $15 Price Target

Benzinga12/06 00:37

Sunshine Biopharma Analyst Ratings

Benzinga12/06 00:35

Sunshine Biopharma Announces Breakthrough Research Results on the Company's K1.1 MRNA Product as a Novel Therapeutic Agent for Human Hepatocellular Carcinoma

Accesswire12/02 21:00

Sunshine Biopharma's Nora Pharma Subsidiary Launches Ursodiol, A Generic Version Of URSO DS

Benzinga11/22 21:05

Sunshine Biopharma Launches a New Generic Prescription Drug

Accesswire11/22 21:00